Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
Its high mechanical characteristics allow effective preservation of the space under the membrane for bone tissue restoration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback